The global cell signaling market accounted for USD 5.42 billion in 2023 and is expected to reach at USD 12.09 billion by 2034 with a CAGR of 7.57% during the forecast period 2024-2034. Rising government funding for the advancement of cell-based research, increasing prevalence of chronic diseases such as cardiovascular conditions, cancer, & neurological disorders, continuous technological advancements in instruments for cell-based research, rising demand for targeted therapies, growing partnerships & collaborations among market participants, ongoing progress in drug development, an escalating demand for personalized medicine, and surge in the introduction of new products focused on cell signaling are some of the key factors boosting the market growth.
Surge in new product launches addressing cell signaling is predicted to boost the market growth during the forecast period. Cell signaling constitutes a component of the communication system responsible for guiding a cell's fundamental operations and harmonizing its various activities. Understanding tissue repair, immunity, and maintaining optimal tissue homeostasis necessitates the interpretation of cellular processes and the coordination of cellular functions. Signal transduction pathways, often known as cell signaling pathways, establish connections between environmental signals and the resultant cellular responses. Comprising proteins capable of interaction, movement to specific locations, and even modification, these signaling pathways play a crucial role in cellular communication. For instance, in September 2023, CST has introduced SignalStar Multiplex IHC technology, an innovative tool designed for spatial biology research that utilizes mid-plex and high-throughput immunohistochemistry (IHC) assays.
By product, consumables was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the repurchasing of consumables, growing focus on personalized medicine & targeted therapies, and the expanding support from both government & private sectors for cell-based research. Additionally, instruments is predicted to grow at the fastest CAGR during the forecast period owing to the growing technological advancements, increasing demand for automated systems, rising demand for Point-of-Care (PoC) diagnostics, surge in the prevalence of chronic diseases, and growing trend of collaborations among market players. For instance, in February 2023, Cell Signalling Technology (CST) and Bio-Techne Corporation have introduced Simple Western validation to CST antibodies. This enhancement aims to streamline the process for researchers from various academic disciplines, providing a dependable and well-established platform to study essential molecular signaling pathways.
By signaling type, endocrine signaling was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the rising occurrence of endocrine-related conditions such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism, & hyperthyroidism, growth in the population of individuals with chronic diseases, and an upsurge in both drug discoveries & therapeutic developments. For instance, in December 2023, Genentech has reported encouraging outcomes from the Phase III INAVO120 trial evaluating the investigational treatment inavolisib in conjunction with palbociclib (Ibrance) and fulvestrant. This combination is being explored as a potential initial treatment for individuals with hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced, or metastatic breast cancer with PIK3CA mutations. Additionally, paracrine signaling is predicted to grow at the fastest CAGR during the forecast period owing to the increasing need for cell-based assays, ongoing progress in proteomics & genomics technology, and rise in interest in regenerative medicine.
By pathway, AKT signaling pathway was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the growing emphasis on developing commercial diagnostic tests that rely on the down-regulation of the AKT pathway, rising prevalence of cancer, increasing number of drugs targeting AKT signaling currently undergoing various stages of clinical trials, and surge in collaborations among market leaders. For instance, in December 2022, Merck KGaA and Mersana Therapeutics have disclosed a collaboration for research and a commercial license agreement. The partnership aims to create cutting-edge antibody-drug conjugates (ADCs) by utilizing Mersana's patented Immunosynthen STING-agonist ADC technology. This joint effort will concentrate on the development of innovative STING-agonist ADCs for a maximum of two targets, utilizing Mersana's platform to conjugate Merck KGaA's proprietary antibodies. Additionally, AMPK signaling pathway is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the incidence of cancer & tumors is associated with the AMPK pathway, which demonstrates both oncogenic and tumor-suppressive effects depending on the tissue-specific tumor microenvironment.
By technology, microscopy was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the upsurge in technological advancements in light microscopy, an expanding need for fluorescence microscopy, and a rise in funding for studies in life science research. Additionally, flow cytometry is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend in the efficient & precise analysis of individual cells in a solution, growing incidence of infectious diseases & cancer, and rise in mergers and acquisitions among participants. For instance, in October 2023, Sino Biological, Inc., a biotechnology firm offering research reagents and associated technical contract research services, has initiated a Share Purchase Agreement for the acquisition of SignalChem Biotech Inc. ("SCB"), a biotechnology company located in Vancouver, Canada.
By application, research was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the growing research & development activities and rising funding for research by major market players. Additionally, medical is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on the development of novel medical products and surge in approval of novel drug products by regulatory bodies. For instance, in November 2023, In the US, Truqap (capivasertib) from AstraZeneca has been approved to treat adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN) when combined with Faslodex (fulvestrant).
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for cell signaling in cancer research, rise in funding for cancer & stem cell research, surge in research & development efforts by major players to develop innovative & advanced products, and growing number of license agreements among market participants. For instance, in January 2023, Cell Signaling Technology (CST) has recently signed a license agreement with Roche to aid in the development of companion diagnostics (CDx). As a prominent global leader in CDx immunoassays, Roche will utilize this agreement to progress and market CDx assays employing CST antibodies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in research & development spending, growing elderly population, advancements in life science infrastructure, rising incidence of chronic diseases, upswing in partnerships among key players, and heightened government funding for research services. For instance, in February 2022, In order to establish cutting-edge stem cell research facilities in 40 prestigious medical research and educational institutes, the Indian government has committed USD 80 million through the Indian Council of Medical Research (ICMR) during the last three years.
Surge in new product launches addressing cell signaling is predicted to boost the market growth during the forecast period. Cell signaling constitutes a component of the communication system responsible for guiding a cell's fundamental operations and harmonizing its various activities. Understanding tissue repair, immunity, and maintaining optimal tissue homeostasis necessitates the interpretation of cellular processes and the coordination of cellular functions. Signal transduction pathways, often known as cell signaling pathways, establish connections between environmental signals and the resultant cellular responses. Comprising proteins capable of interaction, movement to specific locations, and even modification, these signaling pathways play a crucial role in cellular communication. For instance, in September 2023, CST has introduced SignalStar Multiplex IHC technology, an innovative tool designed for spatial biology research that utilizes mid-plex and high-throughput immunohistochemistry (IHC) assays.
By product, consumables was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the repurchasing of consumables, growing focus on personalized medicine & targeted therapies, and the expanding support from both government & private sectors for cell-based research. Additionally, instruments is predicted to grow at the fastest CAGR during the forecast period owing to the growing technological advancements, increasing demand for automated systems, rising demand for Point-of-Care (PoC) diagnostics, surge in the prevalence of chronic diseases, and growing trend of collaborations among market players. For instance, in February 2023, Cell Signalling Technology (CST) and Bio-Techne Corporation have introduced Simple Western validation to CST antibodies. This enhancement aims to streamline the process for researchers from various academic disciplines, providing a dependable and well-established platform to study essential molecular signaling pathways.
By signaling type, endocrine signaling was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the rising occurrence of endocrine-related conditions such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism, & hyperthyroidism, growth in the population of individuals with chronic diseases, and an upsurge in both drug discoveries & therapeutic developments. For instance, in December 2023, Genentech has reported encouraging outcomes from the Phase III INAVO120 trial evaluating the investigational treatment inavolisib in conjunction with palbociclib (Ibrance) and fulvestrant. This combination is being explored as a potential initial treatment for individuals with hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced, or metastatic breast cancer with PIK3CA mutations. Additionally, paracrine signaling is predicted to grow at the fastest CAGR during the forecast period owing to the increasing need for cell-based assays, ongoing progress in proteomics & genomics technology, and rise in interest in regenerative medicine.
By pathway, AKT signaling pathway was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the growing emphasis on developing commercial diagnostic tests that rely on the down-regulation of the AKT pathway, rising prevalence of cancer, increasing number of drugs targeting AKT signaling currently undergoing various stages of clinical trials, and surge in collaborations among market leaders. For instance, in December 2022, Merck KGaA and Mersana Therapeutics have disclosed a collaboration for research and a commercial license agreement. The partnership aims to create cutting-edge antibody-drug conjugates (ADCs) by utilizing Mersana's patented Immunosynthen STING-agonist ADC technology. This joint effort will concentrate on the development of innovative STING-agonist ADCs for a maximum of two targets, utilizing Mersana's platform to conjugate Merck KGaA's proprietary antibodies. Additionally, AMPK signaling pathway is predicted to grow at the fastest CAGR during the forecast period owing to the rise in the incidence of cancer & tumors is associated with the AMPK pathway, which demonstrates both oncogenic and tumor-suppressive effects depending on the tissue-specific tumor microenvironment.
By technology, microscopy was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the upsurge in technological advancements in light microscopy, an expanding need for fluorescence microscopy, and a rise in funding for studies in life science research. Additionally, flow cytometry is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend in the efficient & precise analysis of individual cells in a solution, growing incidence of infectious diseases & cancer, and rise in mergers and acquisitions among participants. For instance, in October 2023, Sino Biological, Inc., a biotechnology firm offering research reagents and associated technical contract research services, has initiated a Share Purchase Agreement for the acquisition of SignalChem Biotech Inc. ("SCB"), a biotechnology company located in Vancouver, Canada.
By application, research was the highest revenue-grossing segment in the global cell signaling market in 2023 owing to the growing research & development activities and rising funding for research by major market players. Additionally, medical is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on the development of novel medical products and surge in approval of novel drug products by regulatory bodies. For instance, in November 2023, In the US, Truqap (capivasertib) from AstraZeneca has been approved to treat adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1, or PTEN) when combined with Faslodex (fulvestrant).
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing demand for cell signaling in cancer research, rise in funding for cancer & stem cell research, surge in research & development efforts by major players to develop innovative & advanced products, and growing number of license agreements among market participants. For instance, in January 2023, Cell Signaling Technology (CST) has recently signed a license agreement with Roche to aid in the development of companion diagnostics (CDx). As a prominent global leader in CDx immunoassays, Roche will utilize this agreement to progress and market CDx assays employing CST antibodies. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in research & development spending, growing elderly population, advancements in life science infrastructure, rising incidence of chronic diseases, upswing in partnerships among key players, and heightened government funding for research services. For instance, in February 2022, In order to establish cutting-edge stem cell research facilities in 40 prestigious medical research and educational institutes, the Indian government has committed USD 80 million through the Indian Council of Medical Research (ICMR) during the last three years.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Cell Signaling Market Report 2023 - 2034
Cell Signaling Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Consumables
- Instruments
Cell Signaling Market Analysis & Forecast by Signaling Type 2023 - 2034 (Revenue USD Bn)
- Synaptic Signaling
- Paracrine Signaling
- Autocrine Signaling
- Endocrine Signaling
- Others
Cell Signaling Market Analysis & Forecast by Pathway 2023 - 2034 (Revenue USD Bn)
- ErbB/HER Signaling Pathway
- AMPK Signaling Pathway
- AKT Signaling Pathway
- Other Signaling Pathways
Cell Signaling Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Western Blotting
- Microscopy
- ELISA
- Flow Cytometry
- Others
Cell Signaling Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Medical
- Research
- Immunology Research
- Cancer Research
- Stem Cell Research
- Others
Cell Signaling Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cell Signaling Market: Product Estimates & Trend Analysis
8. Cell Signaling Market: Signaling Type Estimates & Trend Analysis
9. Cell Signaling Market: Pathway Estimates & Trend Analysis
10. Cell Signaling Market: Technology Estimates & Trend Analysis
11. Cell Signaling Market: Application Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Cell Signaling Market
14. Europe Cell Signaling Market
15. Asia Pacific Cell Signaling Market
16. Latin America Cell Signaling Market
17. MEA Cell Signaling Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Merck KGaA
- Bio-Rad Laboratories Inc.
- Becton
- Dickinson and Company
- Promega Corporation
- PerkinElmer Inc.
- Thermo Fischer Scientific Inc.
- Bio-Techne Corporation
- Qiagen NV
- Cell Signaling Technology Inc.
- Danaher Corporation (Beckman Coulter Inc.)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.42 Billion |
| Forecasted Market Value ( USD | $ 12.09 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
